PTC Therapeutics, Inc.
COMPOUND FORM HAVING ENHANCED BIOAVAILABILITY AND FORMULATIONS THEREOF

Abstract:

The present description generally relates to amorphous forms of compounds having enhanced aqueous solubility and dissolution rates and amorphous solid dispersions and oral pharmaceutical formulations thereof, and to processes for preparing the same. The present description specifically relates to amorphous forms of 5-fluoro-2-(6-fluoro-2-methyl-1H-benzimidazol-1-yl)-N-[4-(trifluoromethyl- )phenyl]pyrimidine-4,6-diamine and amorphous solid dispersions and oral pharmaceutical formulations thereof, and to processes for preparing the same.